• FDA Approves Nerlynx-Capecitabine Combo for HER2-positive Metastatic Breast Cancer
  • New Formulation of Roche’s Perjeta-Herceptin Combo for HER2-Positive Breast Cancer Up for Possible FDA Approval
  • Magseed Approval Extended in Europe for Soft Tissues, Long-Term Implantation
  • Adding Keytruda to Chemo Slows Worsening in Advanced TNBC with PD-L1 Markers, Trial Finds
  • Tucatinib Granted FDA Priority Review for Advanced HER2-positive Breast Cancer
  • Tutu Project’s Pilot Program Helps Breast Cancer Patients Directly With Daily Expenses
  • AutoNation Donates $720K to Breast Cancer Research Foundation
  • Study of Treatment Aiming to Prevent Advanced Breast Cancer’s Spread to Bone Doses 1st Patient
  • Keytruda-Mektovi Combo Deemed Safe in Early Triple Negative Breast Cancer Trial
  • Researcher Awarded $462K NIH Grant to Study Effects of Endocrine Disruptors on Breast Cancer Risk in Young Women
  • Susan G. Komen Tissue Bank Teams with LifeOmic to Advance Breast Cancer Research
  • Ziskin Prize Winners Will Collaborate to Further Immune Checkpoint Inhibitors for Treating Breast Cancer